Press releases
- SHINGRIX approved in Canada for adults at increased risk of shingles due to immunodeficiency or immunosuppression
- For the third consecutive year in a row GSK is named one of Canada’s Top 100 Employers
- NUCALA (mepolizumab) the first and only anti-IL-5 add-on treatment approved in Canada that targets eosinophilic inflammation in adults with chronic rhinosinusitis with nasal polyps (CRSwNP)
